[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602365":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":10,"responsibleParty":32,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Treatment naive,virologically suppressed and unsuppressed treatment experienced in 2nd line",null,[12],"Drug: Biktarvy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Biktarvy","this study applies secondary use of data collected from medical health records",[9],[20],{"name":21,"affiliation":5,"role":22},"Roland LANDMAN","PRINCIPAL_INVESTIGATOR",[24,29],{"name":21,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","40 25 63 54","+33 1","landman.roland@gmail.com",{"name":30,"role":25,"phone":10,"phoneExt":10,"email":31},"Aïda BENALYCHERIF","aida.benalycherif@fondation-imea.org",{"type":33,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100602365","real-world-effectiveness-of-bictegraviremtricitabinetenofovir-alafenamidebicftctaf-in-plwh-in-precarity-settings-in-france--imea073-100602365",false,"NCT07122557","Real World Effectiveness of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide(BIC\u002FFTC\u002FTAF) in PLWH in Precarity Settings in France -IMEA073","Real World Effectiveness of Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide(BIC\u002FFTC\u002FTAF) in PLWH in Precarity Settings in France","PRECARITY","Inclusion Criteria:\n\n* HIV-1 infected patients \\> 18 years during the observation period\n* PLWH with C2S or AME heath insurance coverage information available during the observation period\n* Treatment naive (TN) on BIC\u002FFTC\u002FTAF OR Treatment experienced virologically suppressed (VS TE) or virologically unsupressed (VU TE) in 2d line BIC\u002FFTC\u002FTAF\n* Had at least one follow-up visit after baseline\n\nExclusion Criteria:\n\n* Missing information regarding health insurance coverage\n* On regimen other than BIC\u002FFTC\u002FTAF","ALL","18 Years",{"count":45,"type":46},320,"ESTIMATED","OBSERVATIONAL","In France, French citizens with an annual income less than 10339 euros are considered living with low-income and are eligible to benefit from a public universal healthcare insurance coverage called C2S (complémentaire santé solidaire). C2S covers primary care and hospital care. Non-citizens with low income, like some migrants, can also benefit from a public healthcare insurance coverage called AME (\"Aide Medicale d'Etat\" for State Medical Aid). These criteria are used as a marker of precarity settings (i.e., socio-economic vulnerability) in France. In France, HIV-related care and treatments are reimbursed at 100% (ALD30), whatever the level of precariousness. ART adherence has been shown significantly lower in PLWH with C2S health insurance coverage. Although BIC\u002FFTC\u002FTAF is a recommended preferred option in naive PLWH and in switch or maintenance therapy in most settings, due to the forgiveness profile and the high genetic barrier to resistance, boosted darunavir (DRV\u002Fr) remains even more widely used than 2nd generation InSTIs in populations in precarity settings, and Real World Effectiveness (RWE) with BIC\u002FFTC\u002FTAF is missing to better support its use in these settings.\n\nParis Bichat Hospital (located in one of the poorest districts in the Ile-de-France region) and Nantes university hospital (West France region) follow a cohort of PLWH with a high proportion of populations in precarity settings (i.e with C2S and AME health insurance coverage): Paris Bichat hospital: N=5143 PLWH (December 2021), sex ratio F\u002FM 37\u002F56%, Transgender Women 7%, and born in sub-Saharan African countries 49%. Nantes university hospital: N=2227 PLWH (December 2021), sex ratio F\u002FM 35\u002F65% and born in sub-Saharan African countries 33%. In this cohort of 7370 PLWH in both sites 50% are receiving an InSTI-based ART regimen, regardless of prior treatment history, and at least 40% are receiving care through the C2S or AME, respectively.",[50,51,52,53],"HIV-1","Public Universal Healthcare Insurance Coverage","BIC\u002FFTC\u002FTAF","Low Income Population","NOT_YET_RECRUITING","2025-08-07",{"date":57,"type":58},"2025-08-14","ACTUAL",{"date":60,"type":46},"2025-09",{"date":62,"type":46},"2025-12",{"name":5,"class":6}]